These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 35981786)

  • 1. Single-cell analysis reveals clonally expanded tumor-associated CD57
    Fehlings M; Kim L; Guan X; Yuen K; Tafazzol A; Sanjabi S; Zill OA; Rishipathak D; Wallace A; Nardin A; Ma S; Milojkovic A; Newell EW; Mariathasan S; Yadav M
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
    Holm JS; Funt SA; Borch A; Munk KK; Bjerregaard AM; Reading JL; Maher C; Regazzi A; Wong P; Al-Ahmadie H; Iyer G; Tamhane T; Bentzen AK; Herschend NO; De Wolf S; Snyder A; Merghoub T; Wolchok JD; Nielsen M; Rosenberg JE; Bajorin DF; Hadrup SR
    Nat Commun; 2022 Apr; 13(1):1935. PubMed ID: 35410325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell atlases link macrophages and CD8
    Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
    Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictive and Prognostic Implications of Circulating CX3CR1
    Abdelfatah E; Long MD; Kajihara R; Oba T; Yamauchi T; Chen H; Sarkar J; Attwood K; Matsuzaki J; Segal BH; Dy GK; Ito F
    Cancer Res Commun; 2023 Mar; 3(3):510-520. PubMed ID: 37009132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
    Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell sequencing on CD8
    Komuro H; Shinohara S; Fukushima Y; Demachi-Okamura A; Muraoka D; Masago K; Matsui T; Sugita Y; Takahashi Y; Nishida R; Takashima C; Ohki T; Shigematsu Y; Watanabe F; Adachi K; Fukuyama T; Hamana H; Kishi H; Miura D; Tanaka Y; Onoue K; Onoguchi K; Yamashita Y; Stratford R; Clancy T; Yamaguchi R; Kuroda H; Doi K; Iwata H; Matsushita H
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37544663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface marker-based capture of neoantigen-reactive CD8
    Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep sequencing and flow cytometric characterization of expanded effector memory CD8
    Giudice V; Feng X; Lin Z; Hu W; Zhang F; Qiao W; Ibanez MDPF; Rios O; Young NS
    Haematologica; 2018 May; 103(5):759-769. PubMed ID: 29419434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
    Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
    Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
    [No Abstract]   [Full Text] [Related]  

  • 16. CD28/PD1 co-expression: dual impact on CD8
    Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
    J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
    Ding R; Liu S; Wang S; Chen H; Wang F; Xu Q; Zhu L; Dong X; Gu Y; Zhang X; Chao CC; Gao Q
    Theranostics; 2021; 11(10):4957-4974. PubMed ID: 33754038
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.
    Sun C; Nagaoka K; Kobayashi Y; Maejima K; Nakagawa H; Nakajima J; Kakimi K
    Int J Cancer; 2023 Apr; 152(7):1463-1475. PubMed ID: 36451303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
    Hanada KI; Zhao C; Gil-Hoyos R; Gartner JJ; Chow-Parmer C; Lowery FJ; Krishna S; Prickett TD; Kivitz S; Parkhurst MR; Wong N; Rae Z; Kelly MC; Goff SL; Robbins PF; Rosenberg SA; Yang JC
    Cancer Cell; 2022 May; 40(5):479-493.e6. PubMed ID: 35452604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.